Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

S. Bringhen, M. D'Agostino, L. De Paoli, V. Montefusco, A.M. Liberati, P. Galieni, S. Grammatico, V.E. Muccio, F. Esma, C. De Angelis, P. Musto, S. Ballanti, M. Offidani, M.T. Petrucci, G. Gaidano, P. Corradini, A. Palumbo, P. Sonneveld, M. Boccadoro

Research output: Contribution to journalArticle

Original languageUndefined/Unknown
Pages (from-to)979-985
Number of pages7
JournalLeukemia
Volume32
Issue number4
DOIs
Publication statusPublished - 2018

Cite this

Bringhen, S., D'Agostino, M., De Paoli, L., Montefusco, V., Liberati, A. M., Galieni, P., Grammatico, S., Muccio, V. E., Esma, F., De Angelis, C., Musto, P., Ballanti, S., Offidani, M., Petrucci, M. T., Gaidano, G., Corradini, P., Palumbo, A., Sonneveld, P., & Boccadoro, M. (2018). Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia, 32(4), 979-985. https://doi.org/10.1038/leu.2017.327